Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

Francesco Bonella,Michael Kreuter,Lars Hagmeyer,Claus Neurohr,Claus Keller,Martin J. Kohlhaeufl,Joachim Müller–Quernheim,Katrin Milger,Antje Prasse

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

2016

Francesco Bonella
Michael Kreuter
Lars Hagmeyer
Claus Neurohr
Claus Keller
Martin J. Kohlhaeufl
Joachim Müller–Quernheim
Katrin Milger
Antje Prasse

Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung

Keywords:

Pathology
Compassionate Use
Idiopathic pulmonary fibrosis
Slow disease progression
Intensive care medicine
Lung
Medicine
Nintedanib
FEV1/FVC ratio
Pirfenidone
DLCO
Discontinuation
Pulmonary function testing
Vital capacity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations